Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
Price:
21.4575 USD
0.03%
Market Closed
Updated:
May 6, 2024
Fusion Pharmaceuticals Inc
Cash from Operating Activities
|
Fusion Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Comparables:
ZYME
TH
RPTX
AUPH
EDT
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Operating Activities
-$81.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Operating Activities
-$118.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Operating Activities
-$4m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$127.2m
|
CAGR 3-Years
-176%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
-$33.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-22%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$10.7m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-2%
|
See Also
What is Fusion Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-81.8m
USD
-81.8m
USD
Based on the financial report for Dec 31, 2023, Fusion Pharmaceuticals Inc's Cash from Operating Activities amounts to -81.8m USD.
What is Fusion Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-53%
-53%
Over the last year, the Cash from Operating Activities growth was -12%. The average annual Cash from Operating Activities growth rates for Fusion Pharmaceuticals Inc have been -40% over the past three years , -53% over the past five years .
You don't have any saved screeners yet
